Barclays’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Barclays’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-15	Closed	-$1K	–	6909
2015 Q3	$1K	Buy	+15	New	+$566	﹤0.01%	6697
2015 Q1	–	Sell	-405	Closed	-$8K	–	7350
2014 Q4	$8K	Buy	405 +250	+161%	+$6.88K	﹤0.01%	6850
2014 Q3	$3K	Sell	155 -205	-57%	-$5.42K	﹤0.01%	7357
2014 Q2	$7K	Sell	360 -155	-30%	-$5.01K	﹤0.01%	7024
2014 Q1	$10K	Buy	515 +105	+26%	+$3.98K	﹤0.01%	6942
2013 Q4	$16K	Buy	410 +55	+15%	+$2.15K	﹤0.01%	6829
2013 Q3	$14K	Sell	355 -1,750	-83%	-$102K	﹤0.01%	6673
2013 Q2	$112K	Buy	+2,105	New	+$105K	﹤0.01%	5703

Other funds holding NAVB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Barclays's NAVB Position: Q2 2018 in Review

Barclays held its Navidea Biopharmaceuticals Inc. (NAVB) position steady in Q2 2018 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7509.

Barclays first reported a position in NAVB in Q2 2013 and has held it in 19 quarters since. The position peaked at $234K in Q2 2016. 54 funds tracked by Wall St. Rank hold NAVB as of Q2 2018.

Barclays held 0 shares of Navidea Biopharmaceuticals Inc. worth $0 as of Q2 2018.
Barclays left its Navidea Biopharmaceuticals Inc. share count unchanged in Q2 2018.
Navidea Biopharmaceuticals Inc. made up ﹤0.01% of Barclays's portfolio in Q2 2018, its #7509 holding.
Barclays first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and has held it in 19 quarters since.
Barclays's Navidea Biopharmaceuticals Inc. position peaked at $234K in Q2 2016.
54 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2018.

Based on Barclays's 13F filing for Q2 2018, filed 14 Aug 2018.